Uncomplicated Plasmodium Falciparum Malaria

Infectious Diseases
5
Pipeline Programs
1
Companies
8
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
4
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
5 programs
4
1
KLU156Phase 31 trial
INE963Phase 21 trial
INE963Phase 21 trial
KAE609Phase 21 trial
KAF156Phase 24 trials
Active Trials
NCT07235020Completed52Est. Feb 2025
NCT05750628Recruiting327Est. Jun 2026
NCT07235033Completed60Est. Mar 2025
+5 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
NovartisKLU156
NovartisINE963
NovartisINE963
NovartisKAE609
NovartisKAF156
NovartisKAF156
NovartisKAF156
NovartisKAF156

Clinical Trials (8)

Total enrollment: 3,107 patients across 8 trials

NCT05842954NovartisKLU156

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

Start: Mar 2024Est. completion: Nov 20251,720 patients
Phase 3Completed
NCT07235020NovartisINE963

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria

Start: Jan 2024Est. completion: Feb 202552 patients
Phase 2Completed
NCT05750628NovartisINE963

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Patients With Uncomplicated Plasmodium Falciparum Malaria

Start: Jan 2024Est. completion: Jun 2026327 patients
Phase 2Recruiting
NCT07235033NovartisKAE609

Platform Study to Evaluate the Efficacy and Safety of Anti-malarial Agents in Participants With Uncomplicated Plasmodium Falciparum Malaria (Cohort B2)

Start: Jan 2024Est. completion: Mar 202560 patients
Phase 2Completed
NCT04546633NovartisKAF156

Efficacy, Safety and Tolerability of KAF156 in Combination With Lumefantrine Solid Dispersion Formulation (LUM-SDF) in Pediatric Population With Uncomplicated Plasmodium Falciparum Malaria

Start: Feb 2021Est. completion: Aug 2024295 patients
Phase 2Completed
NCT03167242NovartisKAF156

Efficacy and Safety of KAF156 in Combination With LUM-SDF in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria

Start: Aug 2017Est. completion: Jun 2021524 patients
Phase 2Completed
NCT01753323NovartisKAF156

Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection

Start: Mar 2013Est. completion: Aug 201443 patients
Phase 2Completed
NCT04072302NovartisKAF156

Safety and Causal Prophylactic Efficacy of KAF156 in a Controlled Human Malaria Challenge Model

Start: Sep 2014Est. completion: Nov 201786 patients
Phase 1Completed

Related Jobs in Infectious Diseases

Pharmaceutical Sales Representative Opportunity with Galt Phranchisee, AMRX Pharma, LLC., for the NY Territory

Galt Pharmaceuticals
Hempstead, New York
Yesterday
$82K - $196K/yr

Part-Time Specialty Pharmaceutical Sales Representative  Opportunity with Galt Phranchisee, AMRX Pharma, LLC., for the NY Territory

Galt Pharmaceuticals
Corona, NY, New York
Yesterday
$82K - $196K/yr

Pharmaceutical Sales Representative Opportunity with Galt Phranchisee, AMRX Pharma, LLC., for the NY Territory

Galt Pharmaceuticals
Corona, NY, New York
Yesterday
$82K - $196K/yr

Pharmaceutical Sales Representative Opportunity with Galt Phranchisee, AMRX Pharma, LLC., for the NY Territory

Galt Pharmaceuticals
Bronx, NY, New York
Yesterday
$82K - $196K/yr

Pharmaceutical Sales Representative Opportunity with Galt Phranchisee, AMRX Pharma, LLC., for the NY Territory

Galt Pharmaceuticals
Hempstead, New York
Yesterday
$82K - $196K/yr

Associate Engineer II, Polysaccharide Manufacturing

VaxCyte
San Carlos, California, United States
Yesterday
$54/hr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 3,107 patients
1 companies competing in this space

Related Indications

HIV Infections(582)Influenza(316)COVID-19(241)Hepatitis C(201)HIV(179)Hepatitis B(148)HIV-1-infection(137)HIV Infection(108)Chronic Hepatitis B(105)Malaria(97)